In the present work, we show that ILT2 is also involved in the suppression of NK cells in CLL and we report that the combination of ILT2 blockade with lenalidomide restores NK cell function favoring the elimination of leukemic cells. This evidence concerns the gene LILRB1 and B-cell chronic lymphocytic leukemia.